Teucrium Corn Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Teucrium Corn Fund trades at $18.99 (market cap $125.39M), while State Street SPDR S&P Biotech ETF trades at $153.1 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 80.6× Teucrium Corn Fund's market cap, and Teucrium Corn Fund is more actively traded (271,634 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| CORN | XBI | |
|---|---|---|
Market Cap | $125.39M | $10.11B |
Volume | 271,634 | 12,903,266 |
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $20.29 | $169.55 |
52-Week Low | $16.46 | $104.99 |
Typical Hold Time | 26 Days | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →